Introduction to Vt Ablation

Despite these advances long‐term success rates for VT ablation have remained static and lower in nonischemic than ischemic heart disease because of the more patchy distribution of myocardial scar.

1%) for VT ablation (ICM: 25%, NICM: 59.

The long-term outcome of patients who did not undergo PES after VT ablation remains largely unknown.

OBJECTIVES To provide new insights regarding clinical outcomes based on a large series of VT ablation procedures from the current era in ARVC patients METHODS: We evaluated consecutive patients with definite ARVC who underwent RFA procedures between 2009 and 2019 at our center.

We performed a systematic review and updated meta‐analysis of all available studies evaluating the outcomes of VT ablation by using RMN‐guided compared to manual navigation (MAN)‐guided, with and without CFS catheters.

CONCLUSION Myocardial calcification was present in 19% of post-MI patients referred for VT ablation and was associated with a high incidence of endocardial ablation failure.

The objective of this sub-study of the Ventricular tachycardia AblatioN versus escalated antiarrhythmic drug therapy in ISchemic Heart disease (VANISH) randomized trial was to compare the effectiveness of VT ablation by location of MI in reducing the composite endpoint of all-cause mortality, VT storm, or appropriate ICD therapy when compared to escalated pharmacological therapy in VT patients with a prior MI.

Although evidence suggests that VT ablation could lower the incidence of recurrent VT, many cases still develop VT in follow-up.

Likely principally related to the complex disease substrate, VT ablation is technically challenging, with moderate outcomes, and much remains to be learned.

VT ablation has evolved from a surgical approach to a percutaneous minimally invasive approach.

A MAC strategy should be considered for PVC/VT ablation in the pediatric population.

Prophylactic use of temporary mechanical circulatory support (pro-tMCS) has been applied to prevent AHD during VT ablation, but evidence supporting this practice is still lacking.

Despite advances, use and impact of inotrope and vasodepressor medicines as part of intraprodcedural management during VT ablation have been understudied.

METHODS Forty-three consecutive patients with IDCM underwent a VT ablation procedure with pre-procedure LGE-CMR.

In patients with induced SVTs, SVT ablation without PVI was performed as an index procedure.

After optimisation of antiarrhythmic drugs, a VT ablation procedure was performed in 3 patients during the first 6 months following the ICD treatment because of recurrent VT.

Mapping was performed with the HD Grid catheter to generate high-density maps of cardiac chambers in order to assess the potential influence of the simultaneous orthogonal bipole configuration on PersAF and VT ablation strategies.

2 pts were referred to VT ablation and no recurrence of events was observed after medical therapy modification for the other pts.

Methods To calculate and visualize EGM duration, in sinus rhythm acquired high-density maps of patients with ischemic cardiomyopathy undergoing substrate-based VT ablation using a 64-mini polar basket-catheter with low noise of 0.

The following review will focus on the role of cardiac imaging in risk assessment for VT induction and novel technique and evidence regarding VT therapy including VT ablation and implantable cardiac defibrillator (ICD) therapy.

ES was attributed to catecholamine excess in the setting of these tumors, so VT ablation was deferred pending tumor removal.

A cause–effect relationship hypothesis was raised by the temporal relation with the VT ablation procedure and the presence of a right groin thrill.

The primary end point was the occurrence of ventricular arrhythmia, defined as sustained or non-sustained ventricular tachycardia (VT), more than 500 premature ventricular contractions (PVC) on 24h-holter, or history of VT ablation.

Methods and Results Adjusted competing risk time to event models were developed to adjust for risk of VT recurrence and sustained VT/implantable cardioverter–defibrillator shocks after VT ablation based on patient comorbidities at the time of VT ablation.

ICE has been increasingly used in VT ablation; however, the safety and effectiveness of VT ablation under the combined use of ICE remains unclear.

Because of the electrical storm, a VT ablation was performed immediately.

Patients developing ES were more likely to have a history of VAs, VT ablation, antiarrhythmic drug use, and perioperative mechanical circulatory support around the time of LVAD implant compared with patients without ES.

Class I or class III drugs failed for all patients, and the mean number of VT ablation procedures was 2.

Introduction Programmed electrical stimulation is an essential part of VT ablation procedures but VT is not always inducible, usually for reasons that are not clear.

This study aimed to assess the value of multimodality imaging with cardiac magnetic resonance imaging (CMR), contrast‐enhanced transthoracic echocardiography (TTE), and computed tomography (CT) for thrombus detection as well as a management algorithm geared towards anticoagulation and deferred ablation for patients referred for VT ablation.

These recent advancements provide optimism for improving the clinical outcome of VT ablation in patients with postinfarction, and potentially other scar-related VTs.

Methods This is a multicenter retrospective study including patients with either 1) CS with RV involvement or 2) gene-positive ARVC referred for VT ablation.

As a therapeutic target for ventricular tachycardia (VT), elimination of local abnormal ventricular activities (LAVAs) during sinus rhythm or ventricular pacing has been reported to be a useful and effective endpoint for substrate-based VT ablation.

2 Herein, we report a case of VT ablation in a 67-year-old patient with ischemic cardiomyopathy and severe LV dysfunction who had previously received an LVAD (HeartMate III) implanted as a bridge to heart transplantation.

The use of extracorporeal membrane oxygenation (ECMO) in the setting of haemodynamically unstable VT may allow rhythm stabilization and can be effective in providing haemodynamic stability during VT ablation procedures.

Not surprisingly, VT ablation approaches limited to the endocardiummay confer more limited arrhythmia control.

Phase I subjects included a retrospective cohort with NICM and VT referred for VT ablation between 2007 and 2020 who had detailed substrate mapping.

VT ablation serves as a symptomatic and prognostic therapy in affected patients and has a Class IIa recommendation (level of evidence B) in the European Society of Cardiology guidelines [3].

Patients with and without SHD undergoing SVT ablation exhibit similar success rates and low major complication rates, despite disadvantageous baseline characteristics in SHD patients.

We present the first reported case of VT ablation in the presence of the Tendyne mitral valve prosthesis (Abbott, Santa Clara, CA).

All electrophysiologic centers in Austria that deal with VT ablation are to be integrated into the network in the medium-term.

We report the case of a VT ablation procedure in a patient with history of surgically repaired double-outlet left ventricle.

METHODS AND RESULTS Two hundred and thirty-six patients referred for VT ablation underwent a successful epicardial access and were included in the analysis (89% non-ischaemic cardiomyopathy, 90% males, mean age 60 years, mean left ventricular ejection fraction 38.

This map was integrated with a 3D mapping system to aid in VT ablation.

METHODS This study performed a retrospective evaluation of ten patients (Age: 36±10 y-o) who had been referred for SVT ablation and presented a diagnosis of para-Hisian focal AT confirmed by classical electrophysiological maneuvers.

Integrating pixel signal intensity maps or wall thickness maps delivered from LGE‐CMR or MDCT, respectively, into the navigation system has become a cornerstone for VT ablation procedures in a few centers of excellence around the world.

METHODS We analyzed 234 consecutive procedures of VT ablation in 207 patients (age:63±14.

During the presentation, his VT ablation was performed under unspecified general anaesthesia with veno-arterial extracorporeal membrane oxygen (VA-ECMO) support.

Aim of the present review is to discuss use and benefit of cardiac CT for the planning and preparation of VT ablation.

This case report demonstrates the effectiveness of using RMN system for VT ablation in a teenager with CHD, who underwent open surgical interventions and transcatheter VSD closure using an occluder.

If VT or VF is inducible the patients are referred to ICD implant or VT ablation.

The outcomes assessed were changes in disease severity, frequency of symptoms, heart rate, and blood pressure between before and after SVT ablation.

Real world data suggest that outcomes from VT ablation remain poor in terms of freedom from recurrent therapy using conventional techniques.

Due to recurrent episodes of ventricular tachycardia (VT) despite medical therapy, VT ablation was performed.

Finally, this MA of PLVAD support during VT ablation is based on assumptions, results are mainly driven by one study that includes greater than 80% of patients and should be judged to be of low quality due to marked heterogeneity and serious risk of bias.

8 years’follow-up showed that the success rate of TA-PVC/VT ablation was 81.

Consequently the threshold for referral for VT ablation has fallen over recent years, resulting in increased number of procedures.

It is estimated that, in the next few years, the compound annual growth rate for VT ablation volume will be approximately 7% versus a rate of 17% for AF.

The aim of this meta-analysis was to assess the safety and efficacy of VT ablation prior to or at the time of secondary prevention ICD implantation in patients with coronary artery disease, as compared with deferred VT ablation.

PEFA guided ablation lesions at scar border zone Purpose To investigate the effectiveness of PEFA based VT ablation.

However, the available data from recent studies on VT ablation in DCM are inconsistent and morphological and functional features of the arrhythmogenic substrates are poorly defined.

Upper septal ventricular tachycardia (US-VT) is likely in patients with prior episodes of left posterior fascicular (LPF)-VT ablation, however, little is known about the recurrence mechanism of US-VT.

With the expanding role of VT ablation in patients with significant comorbidity, the choice between the RA and transseptal access routes is an increasingly important consideration.

7 min for VT ablation (p = 0.

To our knowledge, such a case of PE and PDE has not been reported after SVT ablation.

We aimed to investigate the transmural and planar differences of APD in patients admitted for VT ablation.

METHODS We performed a retrospective review of 163 consecutive procedures for PSVT ablation that received Dex as the primary sedative with adjunct fentanyl and midazolam boluses (DEX-FENT-MIDAZ).

The utility of RMCC identification for facilitation of VT ablation in the setting of arrhythmogenic right ventricular cardiomyopathy (ARVC) has not been described.

The coexistence of abnormal innervation and CMR scar may identify a particularly “proarrhythmic” adaptation and may represent a potential novel target for VT ablation.

METHODS We included patients with NICM and mid-myocardial septal substrate referred for VT ablation.

CONCLUSION Stereotactic body radiotherapy appears to show long-term safety and effectiveness for VT ablation in structural heart disease inaccessible to catheter ablation.

Patients with nonischemic etiologies of cardiomyopathy, which are highly prevalent in Asia, have not been previously enrolled in randomized trials of VT ablation.

Consequently, VT ablation represents a growing field in electrophysiology, especially for patients with endocardial scars in ischemic heart disease after myocardial infarction.

Of these, 19 were excluded (VT ablation, n=2; SVT, n=2; unable to induce or sustain AT, n=15).